Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 3, 2021
Distillery Therapeutics

HIV protease inhibitors for dystonia

BioCentury | Sep 10, 2021
Targets & Mechanisms

Integrated stress response key to seemingly disparate diseases?

A flurry of preclinical studies builds the case for the integrated stress response as a central driver of many diseases
BioCentury | Feb 5, 2020
Product Development

WHO prioritizing Gilead’s remdesivir, designing master protocol for 2019-nCoV outbreak

WHO plans to establish master protocol for 2019-nCoV outbreak
BioCentury | Feb 5, 2020
Product Development

冠状病毒爆发:来自编辑的信

BioCentury | Feb 4, 2020
Product Development

The Coronavirus outbreak: Letter from the Editor

BioCentury | Sep 10, 2018
Distillery Therapeutics

Pulmonary

BioCentury | Aug 23, 2018
Distillery Therapeutics

Infectious

BioCentury | Jun 13, 2018
Distillery Therapeutics

Infectious disease

Items per page:
1 - 10 of 471